FDA renames and restructures oncology office
The FDA’s office responsible for approving cancer therapies has been renamed the Office of Oncologic Diseases (OOD) and restructured to add new divisions, the agency announced Wednesday.
OOD, which was previously known as the Office of Hematology and Oncology Products (OHOP), will shift from three clinical divisions and one nonclinical division to six divisions, including three divisions of oncology:
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.